Projects per year
Personal profile
Research interests
I use medicinal chemistry to develop a better understanding of the molecular mechanisms underlying neuropsychological diseases, in particular drug abuse, but also including depression and anxiety. To this end, both highly selective ligands and, more recently, ligands targeted at multiple receptors are designed and synthesized, along with specific pharmacological tools such as irreversible and radiolabeled ligands which allow us to study changes in the chemistry of the brain. Manipulation of the duration of activity of ligands has also been a theme within recent years. I am also interested in the therapeutic potential of such compounds, in particular the group is continuing to study, with the help of funding from the National Institute on Drug Abuse, the utility of opioid ligands as treatment agents for opioid, cocaine and other drugs of abuse and the use of opioid ligands in the treatment of depression. The most important work within the group has been towards ‘selectively promiscuous’ ligands and has been driven by the realisation that CNS disorders are rarely simple, requiring complex solutions. Particular success, and impact, has been achieved in delineating the molecular descriptors that are crucial to the unique pharmacological profile displayed by the opioid treatment agent buprenorphine. This work has allowed us to develop ligands that target multiple opioid receptors simultaneously, with some control over efficacy at each receptor. Current targets include the mu, kappa and NOP opioid receptors and, separately, Regulators of G protein Signaling (RGS) proteins. All our work is carried out in collaboration with colleagues at the University of Bath, the University of Michigan, Torrey Pines Institute for Molecular Studies, Imperial College and the University of Bristol. Current and recent funding for our work has come from the National Institute on Drug Abuse, the Medical Research Council and the Cystic Fibrosis Trust.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Doctor of Philosophy, The cyclopropyl group in enzyme inhibition, University of Strathclyde
Award Date: 1 Jan 1992
Keywords
- QD Chemistry
- Opioid
- medicinal chemistry
- chemical biology
- CNS
- cystic fibrosis
Fingerprint
- 1 Similar Profiles
Network
-
An ultra-portable device for the Instant detection of Synthetic Cannabinoids
Defence Science and Technology Laboratory
1/04/23 → 31/12/23
Project: Central government, health and local authorities
-
IAA - Delivering a commercial answer to the problem of ‘Spice’ entering UK prisons
Pudney, C., Freeman, T., Husbands, S. & Cozier, G.
Engineering and Physical Sciences Research Council
1/11/22 → 31/10/24
Project: Research council
-
Point-of-care detection of synthetic cannabinoid receptor agonists
Pudney, C., Blagbrough, I., Bowman, R., Fincham Haines, T., Freeman, T., Husbands, S. & Scott, J.
Engineering and Physical Sciences Research Council
1/07/21 → 30/06/24
Project: Research council
-
Buvidal and kappa opioid receptor blockade
Bailey, C., Bailey, S. & Husbands, S.
1/07/21 → 1/10/22
Project: Other
-
-
Photochemical Fingerprinting Is a Sensitive Probe for the Detection of Synthetic Cannabinoid Receptor Agonists; Toward Robust Point-of-Care Detection
Andrews, R., May, B., Hernández, F. J., Townsend, P., Cozier, G., Sutcliffe, O. B., Haines, T. S. F., Freeman, T., Scott, J., Husbands, S., Blagbrough, I., Bowman, R., Lewis, S., Grayson, M., Crespo-Otero, R., Carbery, D. & Pudney, C., 17 Jan 2023, In: Analytical Chemistry. 95, 2, p. 703-713Research output: Contribution to journal › Article › peer-review
Open AccessFile35 Downloads (Pure) -
Synthetic Cannabinoid Receptor Agonists are Monoamine Oxidase-A Selective Inhibitors
Hindson, S., Andrews, R., Danson, M., van der Kamp, M., Manley, A., Sutcliffe, O. B., Haines, T. S. F., Freeman, T., Scott, J., Husbands, S., Blagbrough, I., Anderson, R., Carbery, D. & Pudney, C., 28 Jan 2023, (E-pub ahead of print) In: FEBS Journal.Research output: Contribution to journal › Article › peer-review
Open Access -
Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose
Disney, A., Olson, K. M., Anand, J., Shafer, A., Moore, S., Traynor, J. & Husbands, S., 2 Nov 2022, In: ACS Chemical Neuroscience. 13, 21, p. 3108-3117 10 p.Research output: Contribution to journal › Article › peer-review
Open Access -
OREX-1038: A potential new treatment for pain with low abuse liability and limited adverse effects
Gerak, L. R., Maguire, D. R., Cami-Kobeci, G., Olson, K. M., Traynor, J. R., Husbands, S. M., France, C. P., Acevedo, L., Belli, B. & Flynn, P., 1 Sept 2022, In: Behavioural Pharmacology. 33, 6, p. 377-394 18 p.Research output: Contribution to journal › Article › peer-review
-
Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates
Ko, M. C. & Husbands, S. M., 2022, Handbook of Experimental Pharmacology. Springer Science and Business Media Deutschland GmbH, p. 435-452 18 p. (Handbook of Experimental Pharmacology; vol. 271).Research output: Chapter or section in a book/report/conference proceeding › Chapter or section
3 Citations (SciVal)